- Home
- CCEL vs DYAI Comparison
CCEL vs DYAI Comparison
Compare CCEL & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEL | DYAI |
|---|---|---|
| Founded | 1989 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 30.2M |
| IPO Year | 1997 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CCEL | DYAI |
|---|---|---|
| Price | $4.12 | $0.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 3.8K | ★ 540.7K |
| Earning Date | 10-15-2025 | 11-12-2025 |
| Dividend Yield | ★ 10.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,747,500.00 | $3,342,195.00 |
| Revenue This Year | $0.30 | $12.52 |
| Revenue Next Year | N/A | $92.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.57 | $0.71 |
| 52 Week High | $8.86 | $2.20 |
Technical Indicators
Market Signals| Indicator | CCEL | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 48.94 |
| Support Level | $4.04 | $0.85 |
| Resistance Level | $4.08 | $1.03 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 62.79 | 40.21 |
Price Performance
Historical ComparisonAbout CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.